Refractory Sarcoidosis: A Review

References

• Besnier EH. Lupus pernio de la face; synovites fongueuses (scrofulo-tuberculeuses) symétriques des extrémités supérieures. Ann Dermatol Syphil. 1889;333–336.
   Google Scholar
• Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol. 2017;24(1):59–65. doi:10.1097/MOH.0000000000000301
   PubMed Web of Science ®Google Scholar
• Hunninghake G, Costabel U. Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160:20. doi:10.1034/j.1399-3003.1999.14d02.x
   Web of Science ®Google Scholar
• Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis. 2018;9(11):227–240. doi:10.1177/2040622318790197
   PubMed Web of Science ®Google Scholar
• Pereira CAC, Dornfeld MC, Baughman R, Judson MA. Clinical phenotypes in sarcoidosis. Curr Opin Pulm Med. 2014;20(5):496–502. doi:10.1097/MCP.0000000000000077
   PubMed Web of Science ®Google Scholar
• Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P-Y, Müller-Quernheim J. Sarcoidosis. The Lancet. 2014;383(9923):1155–1167. doi:10.1016/S0140-6736(13)60680-7
   PubMed Web of Science ®Google Scholar
• Nunes H, Bouvry D, Soler P, Valeyre D. Sarcoidosis. Orphanet J Rare Dis. 2007;2(1):46. doi:10.1186/1750-1172-2-46
   PubMed Web of Science ®Google Scholar
• Crouser ED. Lessons learned from the ABCs of granuloma formation. Am J Respir Cell Mol Biol. 2019;61(3):277–278. doi:10.1165/rcmb.2019-0076ED
   PubMed Web of Science ®Google Scholar
• Goto H, Usui Y, Umazume A, Uchida K, Eishi Y. Propionibacterium acnes as a possible pathogen of granuloma in patients with ocular sarcoidosis. Br J Ophthalmol. 2017;101(11):1510–1513. doi:10.1136/bjophthalmol-2016-309248
   PubMed Web of Science ®Google Scholar
• Pacheco Y, Ponchon M, Lebecque S, et al. Granulomatous lung inflammation is nanoparticle type dependent. Exp Lung Res. 2018;44(1):25–39. doi:10.1080/01902148.2017.1412541
   PubMed Web of Science ®Google Scholar
• Mortaz E, Adcock IM, Abedini A, et al. The role of pattern recognition receptors in lung sarcoidosis. Eur J Pharmacol. 2017;808:44–48. doi:10.1016/j.ejphar.2017.01.020
   PubMed Web of Science ®Google Scholar
• Rivera A, Siracusa MC, Yap GS, Gause WC. Innate cell communication kick-starts pathogen-specific immunity. Nat Immunol. 2016;17(4):356–363. doi:10.1038/ni.3375
   PubMed Web of Science ®Google Scholar
• Zissel G, Müller-Quernheim J. Cellular players in the immunopathogenesis of sarcoidosis. Clin Chest Med. 2015;36(4):549–560. doi:10.1016/j.ccm.2015.08.016
   PubMed Web of Science ®Google Scholar
• Roach DR, Bean AGD, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002;168(9):4620–4627. doi:10.4049/jimmunol.168.9.4620
   PubMed Web of Science ®Google Scholar
• Ramstein J, Broos CE, Simpson LJ, et al. IFN-γ–producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med. 2016;193(11):1281–1291. doi:10.1164/rccm.201507-1499OC
   PubMed Web of Science ®Google Scholar
• Calender A, Lim CX, Weichhart T, et al. Exome sequencing and pathogenicity-network analysis of 5 French families implicate mTOR signalling and autophagy in familial sarcoidosis. Eur Respir J. 2019;54:2. doi:10.1183/13993003.00430-2019
   Web of Science ®Google Scholar
• Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. Semin Arthritis Rheum. 2017;47(2):288–294. doi:10.1016/j.semarthrit.2017.03.005
   PubMed Web of Science ®Google Scholar
• Korsten P, Strohmayer K, Baughman RP, Sweiss NJ. Refractory pulmonary sarcoidosis: proposal of a definition and recommendations for the diagnostic and therapeutic approach. Clin Pulm Med. 2016;23(2):67–75. doi:10.1097/CPM.0000000000000136
   PubMedGoogle Scholar
• Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–1528. doi:10.1183/09031936.00224513
   PubMed Web of Science ®Google Scholar
• Judson MA, Costabel U, Drent M, et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 31:19–27.
   PubMed Web of Science ®Google Scholar
• Bickett AN, Lower EE, Baughman RP. Sarcoidosis diagnostic score. Chest. 2018;154(5):1052–1060. doi:10.1016/j.chest.2018.05.003
   PubMed Web of Science ®Google Scholar
• Criado E, Sánchez M, Ramírez J, et al. Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation. RadioGraphics. 2010;30(6):1567–1586. doi:10.1148/rg.306105512
   PubMed Web of Science ®Google Scholar
• Park HJ, Jung JI, Chung MH, et al. Typical and atypical manifestations of intrathoracic sarcoidosis. Korean J Radiol. 2009;10(6):623. doi:10.3348/kjr.2009.10.6.623
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Luppi F, Roversi P, Cerri S, Fabbri LM, Richeldi L. Sarcoidosis: challenging diagnostic aspects of an old disease. Am J Med. 2012;125(2):118–125. doi:10.1016/j.amjmed.2011.06.003
   PubMed Web of Science ®Google Scholar
• Chalayer É, Bachy E, Occelli P, et al. Sarcoidosis and lymphoma: a comparative study. QJM. 2015;108(11):871–878. doi:10.1093/qjmed/hcv039
   PubMed Web of Science ®Google Scholar
• Gousseff M, Mechaï F, Lecuit M, Lortholary O. Les granulomatoses systémiques d’origine infectieuse. La Revue De Médecine Interne. 2008;29(1):15–27. doi:10.1016/j.revmed.2007.09.037
   PubMed Web of Science ®Google Scholar
• Piotrowski WJ, Żądło LJ, Górski W, et al. QuantiFERON-TB-GOLD In-Tube in patients with sarcoidosis. Advan Respir Med. 2018;86(5):234–239. doi:10.5603/ARM.2018.0037
   PubMed Web of Science ®Google Scholar
• O’Sullivan CE, Miller DR, Schneider PS, Roberts GD. Evaluation of gen-probe amplified mycobacterium tuberculosis direct test by using respiratory and nonrespiratory specimens in a tertiary care center laboratory. J Clin Microbiol. 2002;40(5):1723–1727. doi:10.1128/JCM.40.5.1723-1727.2002
   PubMed Web of Science ®Google Scholar
• Dhooria S, Gupta N, Bal A. Role of Xpert MTB/RIF in differentiating tuberculosis from sarcoidosis in patients with mediastinal lymphadenopathy undergoing EBUS-TBNA: a study of 147 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(3):258–266.
   PubMed Web of Science ®Google Scholar
• James DG, Lipman MCI. Whipple’s disease: a granulomatous masquerader. Clin Chest Med. 2002;23(2):513–519. doi:10.1016/S0272-5231(02)00005-9
   PubMed Web of Science ®Google Scholar
• Ohshimo S, Guzman J, Costabel U, Bonella F. Differential diagnosis of granulomatous lung disease: clues and pitfalls: number 4 in the Series “Pathology for the clinician” Edited by Peter Dorfmüller and Alberto Cavazza. Eur Respir Rev. 2017;26(145):170012. doi:10.1183/16000617.0012-2017
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Mañá J, Nardi N, et al. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine. 2005;84(2):69–80. doi:10.1097/01.md.0000157577.69729.e6
   PubMed Web of Science ®Google Scholar
• Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-induced sarcoidosis-like reactions. Chest. 2018;154(3):664–677. doi:10.1016/j.chest.2018.03.056
   PubMed Web of Science ®Google Scholar
• Cohen Aubart F, Lhote R, Amoura A, et al. Drug‐induced sarcoidosis: an overview of the WHO pharmacovigilance database. J Intern Med. 2019. doi:10.1111/joim.12991
   PubMed Web of Science ®Google Scholar
• Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34–44. doi:10.1016/j.ejca.2017.05.032
   PubMed Web of Science ®Google Scholar
• Seve P, Jamilloux Y, Gerfaud-Valentin M, El-Jammal T, Pavic M. Faut-il rechercher un cancer après la découverte d’une granulomatose inexpliquée? La Revue de Médecine Interne. 2019;40(8):487–490. doi:10.1016/j.revmed.2019.05.006
   PubMed Web of Science ®Google Scholar
• Bouvry D, Mouthon L, Brillet P-Y, et al. Granulomatosis-associated common variable immunodeficiency disorder: a case-control study versus sarcoidosis. Eur Respir J. 2013;41(1):115–122. doi:10.1183/09031936.00189011
   PubMed Web of Science ®Google Scholar
• Wu C, Wang R, Chen B, et al. Granuloma with an underlying Lymphoma A diagnostic challenge and a wider histologic spectrum including adult T-cell leukemia/lymphoma. Appl Immunohistochem Mol Morphol. 2019:1. doi:10.1097/PAI.0000000000000731.
   PubMedGoogle Scholar
• Brincker H. The sarcoidosis-lymphoma syndrome. Br J Cancer. 1986;54(3):467–473. doi:10.1038/bjc.1986.199
   PubMed Web of Science ®Google Scholar
• Bernard C, Maucort-Boulch D, Varron L, et al. Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases. QJM. 2013;106(6):523–539. doi:10.1093/qjmed/hct052
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Néel A, Lecouffe-Desprets M, et al. Progressive multifocal leukoencephalopathy in patients with sarcoidosis. Neurology. 2014;82(15):1307–1313. doi:10.1212/WNL.0000000000000318
   PubMed Web of Science ®Google Scholar
• Martusewicz-Boros MM, Boros PW, Wiatr E, Fijołek J, Roszkowski-Śliż K. Systemic treatment for sarcoidosis was needed for 16% of 1810 Caucasian patients. Clin Respir J. 2018;12(4):1367–1371. doi:10.1111/crj.12664
   PubMed Web of Science ®Google Scholar
• Paramothayan NS, Lasserson TJ, Jones P. Corticosteroids for pulmonary sarcoidosis. Cochrane Airways Group, ed. Cochrane Database of Syst Rev. 2005. doi:10.1002/14651858.CD001114.pub2
   Web of Science ®Google Scholar
• Broos CE, Wapenaar M, Looman CWN, et al. Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis. Eur Respir J. 2018;51(1):1702089. doi:10.1183/13993003.02089-2017
   PubMed Web of Science ®Google Scholar
• Mahévas M, Lescure FX, Boffa -J-J, et al. Renal Sarcoidosis: clinical, Laboratory, and Histologic Presentation and Outcome in 47 Patients. Medicine. 2009;88(2):98–106. doi:10.1097/MD.0b013e31819de50f
   PubMed Web of Science ®Google Scholar
• McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of Short-Course, Low-Dose Corticosteroid Therapy for Acute Pulmonary Sarcoidosis Exacerbations. Am J Med Sci. 2010;339(1):1–4. doi:10.1097/MAJ.0b013e3181b97635
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Treatment of Sarcoidosis. Clin Rev Allergy Immunol. 2015;49(1):79–92. doi:10.1007/s12016-015-8492-9
   PubMed Web of Science ®Google Scholar
• Noe MH, Rosenbach M. Cutaneous sarcoidosis. Curr Opin Pulm Med. 2017;23(5):482–486. doi:10.1097/MCP.0000000000000402
   PubMed Web of Science ®Google Scholar
• Yang SJ, Salek S, Rosenbaum JT. Ocular sarcoidosis: new diagnostic modalities and treatment. Curr Opin Pulm Med. 2017;23(5):458–467. doi:10.1097/MCP.0000000000000409
   PubMed Web of Science ®Google Scholar
• Ho JSY, Chilvers ER, Thillai M. Cardiac sarcoidosis – an expert review for the chest physician. Expert Rev Respir Med. 2019;13(6):507–520. doi:10.1080/17476348.2018.1511431
   PubMed Web of Science ®Google Scholar
• Shelke AB, Aurangabadkar HU, Bradfield JS, Ali Z, Kumar KS, Narasimhan C. Serial FDG-PET scans help to identify steroid resistance in cardiac sarcoidosis. Int J Cardiol. 2017;228:717–722. doi:10.1016/j.ijcard.2016.11.142
   PubMed Web of Science ®Google Scholar
• Bitoun S, Bouvry D, Borie R, et al. Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology. 2016;87(24):2517–2521. doi:10.1212/WNL.0000000000003431
   PubMed Web of Science ®Google Scholar
• Cohen Aubart F, Bouvry D, Galanaud D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol. 2017;264(5):891–897. doi:10.1007/s00415-017-8444-9
   PubMed Web of Science ®Google Scholar
• Stern BJ, Royal W, Gelfand JM, et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018;75(12):1546. doi:10.1001/jamaneurol.2018.2295
   PubMed Web of Science ®Google Scholar
• Wengert O, Rothenfusser-Korber E, Vollrath B, et al. Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J Neurol Sci. 2013;335(1–2):124–130. doi:10.1016/j.jns.2013.09.008
   PubMed Web of Science ®Google Scholar
• Hilderson I, Van Laecke S, Wauters A, Donck J. Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options. Nephrol Dialysis Transplant. 2014;29(10):1841–1847. doi:10.1093/ndt/gft442
   PubMed Web of Science ®Google Scholar
• Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a delphi consensus study. Respir Med. 2010;104(5):717–723. doi:10.1016/j.rmed.2009.12.009
   PubMed Web of Science ®Google Scholar
• Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids. Chest. 1999;115(4):1158–1165. doi:10.1378/chest.115.4.1158
   PubMed Web of Science ®Google Scholar
• Grutters JC, van den Bosch JMM. Corticosteroid treatment in sarcoidosis. Eur Respir J. 2006;28(3):627–636. doi:10.1183/09031936.06.00105805
   PubMed Web of Science ®Google Scholar
• Al-Kofahi K, Korsten P, Ascoli C, et al. Management of extrapulmonary sarcoidosis: challenges and solutions. Ther Clin Risk Manag. 2016;12:1623–1634. doi:10.2147/TCRM.S74476
   PubMed Web of Science ®Google Scholar
• Judson M. Extrapulmonary Sarcoidosis. Semin Respir Crit Care Med. 2007;28(1):083–101. doi:10.1055/s-2007-970335
   PubMed Web of Science ®Google Scholar
• Matsou A, Tsaousis KT. Management of chronic ocular sarcoidosis: challenges and solutions. OPTH. 2018;12:519–532. doi:10.2147/OPTH.S128949
   Web of Science ®Google Scholar
• Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther. 2019;19(5):477–490. doi:10.1080/14712598.2019.1595578
   PubMed Web of Science ®Google Scholar
• Baughman RP. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;60–66.
   PubMed Web of Science ®Google Scholar
• Cremers JP, Drent M, Bast A, et al. Multinational evidence-based world association of sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19(5):545–561. doi:10.1097/MCP.0b013e3283642a7a
   PubMed Web of Science ®Google Scholar
• Lower E. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155(8):846–851. doi:10.1001/archinte.1995.00430080088011
   PubMedGoogle Scholar
• Mainman H, McClaren E, Heycock C, Saravanan V, Hamilton J, Kelly C. When should we use parenteral methotrexate? Clin Rheumatol. 2010;29(10):1093–1098. doi:10.1007/s10067-010-1500-9
   PubMed Web of Science ®Google Scholar
• Shea B, Swinden MV, Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014;41(6):1049–1060. doi:10.3899/jrheum.130738
   PubMed Web of Science ®Google Scholar
• Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160(1):192–197. doi:10.1164/ajrccm.160.1.9809024
   PubMed Web of Science ®Google Scholar
• Judson M, Barba, Beegle, Gobunsuy. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther. 2013;325. doi:10.2147/DDDT.S31064
   PubMed Web of Science ®Google Scholar
• Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16(1):220. doi:10.1186/s12883-016-0741-x
   PubMed Web of Science ®Google Scholar
• Arthritis in Sarcoidosis Group (ASG), Agarwal V, Agrawal V, et al. Arthritis in sarcoidosis: a multicentric study from India. Int J Rheum Dis. 2018;21(9):1728–1733. doi:10.1111/1756-185X.13349.
   PubMed Web of Science ®Google Scholar
• Tselios K, Deeb M, Gladman DD, Harvey P, Urowitz MB. Antimalarial-induced cardiomyopathy: a systematic review of the literature. Lupus. 2018;27(4):591–599. doi:10.1177/0961203317734922
   PubMed Web of Science ®Google Scholar
• Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75(1):25–34. doi:10.1016/0002-9343(83)91267-6
   PubMed Web of Science ®Google Scholar
• Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111(8):3. doi:10.1172/JCI200318384
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–812. doi:10.1378/chest.12-1728
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology. 2000;39(6):655–665. doi:10.1093/rheumatology/39.6.655
   PubMed Web of Science ®Google Scholar
• Baughman RP. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(1):43–48. doi:10.1007/s11083-004-5178-y
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145–1150. doi:10.1183/09031936.00195010
   PubMed Web of Science ®Google Scholar
• Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology. 2011;76(13):1168–1172. doi:10.1212/WNL.0b013e318212aafb
   PubMed Web of Science ®Google Scholar
• Bhat P, Cervantes-Castañeda RA, Doctor PP, Anzaar F, Foster CS. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm. 2009;17(3):185–190. doi:10.1080/09273940902862992
   PubMed Web of Science ®Google Scholar
• Chapelon-Abric C, Sene D, Saadoun D, et al. Cardiac sarcoidosis: diagnosis, therapeutic management and prognostic factors. Arch Cardiovasc Dis. 2017;110(8–9):456–465. doi:10.1016/j.acvd.2016.12.014
   PubMed Web of Science ®Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest. 2003;124(5):2023–2026. doi:10.1378/chest.124.5.2023
   PubMed Web of Science ®Google Scholar
• Varron L, Broussolle C, Candessanche J-P, et al. Spinal cord sarcoidosis: report of seven cases. Eur J Neurol. 2009;16(3):289–296. doi:10.1111/j.1468-1331.2008.02409.x
   PubMed Web of Science ®Google Scholar
• Baughman RP. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(3):310.
   Web of Science ®Google Scholar
• Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis. Chest. 2005;128(2):1062–1067. doi:10.1016/S0012-3692(15)50471-6
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31(6):1189–1196. doi:10.1183/09031936.00051907
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802. doi:10.1164/rccm.200603-402OC
   PubMed Web of Science ®Google Scholar
• Rossman M. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(3):201–208.
   PubMed Web of Science ®Google Scholar
• Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–773. doi:10.1016/j.jaad.2012.10.056
   PubMed Web of Science ®Google Scholar
• Erckens RJ, Mostard RLM, Wijnen PAHM, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefe’s Arch Clin Exp Ophthalmol. 2012;250(5):713–720. doi:10.1007/s00417-011-1844-0
   PubMed Web of Science ®Google Scholar
• Adler BL, Wang CJ, Bui T-L, Schilperoort HM, Armstrong AW. Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety. Semin Arthritis Rheum. 2019;48(6):1093–1104. doi:10.1016/j.semarthrit.2018.10.005
   PubMed Web of Science ®Google Scholar
• Schimmelpennink MC, Vorselaars ADM, van Beek FT, et al. Efficacy and safety of infliximab biosimilar Inflectra ® in severe sarcoidosis. Respir Med. 2018;138:S7–S13. doi:10.1016/j.rmed.2018.02.009
   PubMed Web of Science ®Google Scholar
• Barba T, Marquet A, Bouvry D, et al. Efficacy and safety of infliximab therapy in refractory upper respiratory tract sarcoidosis: experience from the STAT registry. Sarcoidosis Vasc Diffuse Lung Dis. 2018;34(4):343–351.
   Web of Science ®Google Scholar
• Marquet A, Chapelon-Abric C, Maucort-Boulch D, et al. Efficacy and safety of TNF antagonists in ocular sarcoidosis: data from the French registry STAT. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(1):74.
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation. 2003;107(25):3133–3140. doi:10.1161/01.CIR.0000077913.60364.D2
   PubMed Web of Science ®Google Scholar
• Puyraimond-Zemmour D, Chapelon-Abric C, Bouvry D, Ruivard M, André M, Pérard L. Efficacy and tolerance of TNF alpha inhibitor treatment in cardiac sarcoidosis. Int J Exp Clin Res. 2018;2018:1.
   Google Scholar
• Harper LJ, McCarthy M, Ribeiro Neto ML, et al. Infliximab for refractory cardiac sarcoidosis. Am J Cardiol. 2019:S0002914919309555. doi:10.1016/j.amjcard.2019.07.067.
   Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296–1307. doi:10.1183/09031936.00000914
   PubMed Web of Science ®Google Scholar
• Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology. 2009;14(4):522–528. doi:10.1111/j.1440-1843.2009.01518.x
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Verwoerd A, van Moorsel CHM, Keijsers RGM, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J. 2014;43(2):602–609. doi:10.1183/09031936.00055213
   PubMed Web of Science ®Google Scholar
• Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of tnf-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91–107.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108(6):962–971. doi:10.1038/ajg.2013.12
   PubMed Web of Science ®Google Scholar
• Bloem K, van Leeuwen A, Verbeek G, et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods. 2015;418:29–38. doi:10.1016/j.jim.2015.01.007
   PubMed Web of Science ®Google Scholar
• Crommelin HA, van der Burg LM, Vorselaars ADM, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72–77. doi:10.1016/j.rmed.2016.04.011
   PubMed Web of Science ®Google Scholar
• Thery-Casari C, Jamilloux Y, Bouvry D, et al. Outcome of patients with sarcoidosis refractory to TNF antagonists: a case series. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35:371–375.
   PubMed Web of Science ®Google Scholar
• Saussine A, Tazi A, Feuillet S, et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF Levels. Hoshino Y, ed. PLoS One. 2012;7(8):e43588. doi:10.1371/journal.pone.0043588
   PubMed Web of Science ®Google Scholar
• Beccastrini E, Vannozzi L, Bacherini D, Squatrito D, Emmi L. Successful treatment of ocular sarcoidosis with rituximab. Ocul Immunol Inflamm. 2013;21(3):244–246. doi:10.3109/09273948.2012.762982
   PubMed Web of Science ®Google Scholar
• Cinetto F, Compagno N, Scarpa R, Malipiero G, Agostini C. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy. 2015;13:1. doi:10.1186/s12948-015-0025-9
   PubMedGoogle Scholar
• Gottenberg J-E. Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64(6):913–920. doi:10.1136/ard.2004.029694
   PubMed Web of Science ®Google Scholar
• Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thöne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018;11:175628641880573. doi:10.1177/1756286418805732
   Web of Science ®Google Scholar
• Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75(6):568–570. doi:10.1212/WNL.0b013e3181ec7ff9
   PubMed Web of Science ®Google Scholar
• Sawaya R, Radwan W. Sarcoidosis associated with neuromyelitis optica. J Clin Neurosci. 2013;20(8):1156–1158. doi:10.1016/j.jocn.2012.09.030
   PubMed Web of Science ®Google Scholar
• Baughman R, Lower K. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol. 2012;1613. doi:10.2147/OPTH.S35521
   PubMedGoogle Scholar
• van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761–1766. doi:10.3899/jrheum.150051
   PubMed Web of Science ®Google Scholar
• Girgis RE, Basha MA, Maliarik M, Popovich J, Iannuzzi MC. Cytokines in the bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis. Am J Respir Crit Care Med. 1995;152(1):71–75. doi:10.1164/ajrccm.152.1.7599865
   PubMed Web of Science ®Google Scholar
• Awano N, Inomata M, Kondoh K, et al. Mixed-type multicentric castleman’s disease developing during a 17-year follow-up of sarcoidosis. Internal Med. 2012;51(21):3061–3066. doi:10.2169/internalmedicine.51.8120
   PubMed Web of Science ®Google Scholar
• Semiz H, Kobak S. Coexistence of sarcoidosis and adult onset Still disease. Reumatología Clínica. 2017. doi:10.1016/j.reuma.2017.04.004
   Web of Science ®Google Scholar
• Sharp M, Donnelly SC, Moller DR. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respir Med. 2019;1:100004. doi:10.1016/j.yrmex.2019.100004
   Google Scholar
• Silpa-archa S, Oray M, Preble JM, Foster CS. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol (Copenh). 2016;94(6):e400–e406. doi:10.1111/aos.13015
   PubMed Web of Science ®Google Scholar
• Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol. 2019;200:85–94. doi:10.1016/j.ajo.2018.12.019
   PubMed Web of Science ®Google Scholar
• Nutz A, Pernet C, Combe B, Cohen J-D. Sarcoidosis induced by tocilizumab: a paradoxical event? J Rheumatol. 2013;40(10):1773–1774. doi:10.3899/jrheum.130278
   PubMed Web of Science ®Google Scholar
• Bustamente L. Sarcoidosis and tocilizumab: is there a link? Clin Exp Rheumatol. 2017;35(4):716.
   PubMed Web of Science ®Google Scholar
• Del Giorno R, Iodice A, Mangas C, Gabutti L. New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review. Ther Adv Musculoskelet Dis. 2019;11:1759720X1984179. doi:10.1177/1759720X19841796
   PubMed Web of Science ®Google Scholar
• Shono Y, Kamata M, Takeoka S, et al. Cutaneous sarcoidosis in a patient with rheumatoid arthritis receiving tocilizumab. J Dermatol. 2018;45(8):e217–e218. doi:10.1111/1346-8138.14268
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Hessellund A, Phan I, Planck SR, Wilson DJ. The expression of STAT-1 and phosphorylated STAT-1 in conjunctival granulomas. Ocul Immunol Inflamm. 2010;18(4):261–264. doi:10.3109/09273941003797934
   PubMed Web of Science ®Google Scholar
• Levraut M, Martis N, Viau P, Suarez F, Queyrel V. Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib. Ann Rheum Dis. 2019;annrheumdis-2019-215387. doi:10.1136/annrheumdis-2019-215387
   PubMed Web of Science ®Google Scholar
• Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540–2546. doi:10.1056/NEJMoa1805958
   PubMed Web of Science ®Google Scholar
• Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2019. doi:10.1016/j.jaad.2019.05.098
   Web of Science ®Google Scholar
• Wei JJ, Kallenbach LR, Kreider M, Leung TH, Rosenbach M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 2019;5(4):360–361. doi:10.1016/j.jdcr.2019.02.006
   PubMedGoogle Scholar
• Rotenberg C, Besnard V, Brillet P-Y, Giraudier S, Nunes H, Valeyre D. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018;52(6):1801482. doi:10.1183/13993003.01482-2018
   PubMed Web of Science ®Google Scholar
• El Jammal T, Gerfaud-Valentin M, Sève P, Jamilloux Y. Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum. Joint Bone Spine. 2019;S1297319X19301265. doi:10.1016/j.jbspin.2019.09.005
   Web of Science ®Google Scholar
• Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology. 2019;58(10):1755–1766. doi:10.1093/rheumatology/kez087
   PubMed Web of Science ®Google Scholar
• Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med. 1997;156(5):1371–1376. doi:10.1164/ajrccm.156.5.9506031
   PubMed Web of Science ®Google Scholar
• Bogabathina H, Olson P, Rathi VK, Biederman RWW. Cardiac sarcoidosis or giant cell myocarditis? On treatment improvement of fulminant myocarditis as demonstrated by cardiovascular magnetic resonance imaging. Case Rep Cardiol. 2012;2012:1–5. doi:10.1155/2012/647041
   Google Scholar
• Linke M, Pham HTT, Katholnig K, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017;18(3):293–302. doi:10.1038/ni.3655
   PubMed Web of Science ®Google Scholar
• Manzia TM, Bellini MI, Corona L, et al. Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation: letter to the editors. Transplant Int. 2011;24(8):e69–e70. doi:10.1111/j.1432-2277.2011.01256.x
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Sepah YJ, Watters A, et al. One-Year Outcomes of the SAVE Study: S irolimus as a therapeutic A pproach for U VE itis. Transl Vis Sci Technol. 2015;4(2):4. doi:10.1167/tvst.4.2.4
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Sadiq MA, Agarwal A. The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis (An american ophthalmological society thesis). Trans Am Ophthalmol Soc. 2016;14.
   Google Scholar
• Nguyen QD, Merrill PT, Clark WL, et al. Intravitreal sirolimus for noninfectious uveitis: a phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA). Ophthalmology. 2016;123(11):2413–2423. doi:10.1016/j.ophtha.2016.07.029
   PubMed Web of Science ®Google Scholar
• Droitcourt C, Rybojad M, Porcher R, et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest. 2014;146(4):1046–1054. doi:10.1378/chest.14-0015
   PubMed Web of Science ®Google Scholar
• Fazzi P, Manni E, Cristofani R, et al. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomed Pharmacother. 2012;66(4):300–307. doi:10.1016/j.biopha.2012.03.005
   PubMed Web of Science ®Google Scholar
• Huddleston SM, Houser KH, Walton RC. Thalidomide for recalcitrant nodular scleritis in sarcoidosis. JAMA Ophthalmol. 2014;132(11):1377. doi:10.1001/jamaophthalmol.2014.2420
   PubMed Web of Science ®Google Scholar
• Giv MJ, Yoosuff A, Bazargan A. Use of lenalidomide in 5q-myelodysplastic syndrome provides novel treatment prospects in management of pulmonary sarcoidosis. Chest. 2015;148(2):e35–e37. doi:10.1378/chest.14-2529
   PubMed Web of Science ®Google Scholar
• Baughman RP. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol. 2012;148(2):262. doi:10.1001/archdermatol.2011.301
   PubMedGoogle Scholar
• Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. 2015;3(10):813–822. doi:10.1016/S2213-2600(15)00199-X
   PubMed Web of Science ®Google Scholar
• Chopra I, Qin Y, Kranyak J, et al. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records. Ther Adv Respir Dis. 2019;13:175346661988812. doi:10.1177/1753466619888127
   Web of Science ®Google Scholar
• Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155(5):1665–1669. doi:10.1164/ajrccm.155.5.9154873
   PubMed Web of Science ®Google Scholar
• Park MK, Fontana JR, Babaali H, et al. Steroid-Sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):121–131.
   PubMed Web of Science ®Google Scholar
• Drake WP, Oswald-Richter K, Richmond BW, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013;149(9):1040. doi:10.1001/jamadermatol.2013.4646
   PubMed Web of Science ®Google Scholar
• Drake WP, Richmond BW, Oswald-Richter K, et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(3):201–211.
   PubMed Web of Science ®Google Scholar
• Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Annals ATS. 2013;10(4):362–370. doi:10.1513/AnnalsATS.201303-069FR
   Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528. doi:10.1056/NEJMoa1903076
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–1727. doi:10.1056/NEJMoa1908681
   PubMed Web of Science ®Google Scholar
• Kang S. Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiat Oncol Investig. 1999;7(5):309–312. doi:10.1002/(SICI)1520-6823(1999)7:5<309::AID-ROI6>3.0.CO;2-W
   PubMedGoogle Scholar
• Valeyre D, Jeny F, Nunes H. Current medical therapy for sarcoidosis. Semin Respir Crit Care Med. 2017;38(04):523–531. doi:10.1055/s-0037-1604032
   PubMed Web of Science ®Google Scholar
• Parambil JG, Tavee JO, Zhou L, Pearson KS, Culver DA. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med. 2011;105(1):101–105. doi:10.1016/j.rmed.2010.09.015
   PubMed Web of Science ®Google Scholar
• Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med. 2017;126:135–138. doi:10.1016/j.rmed.2017.03.011
   PubMed Web of Science ®Google Scholar
• Kono M, Kono M, Jodo S. A case of refractory acute sarcoid myopathy successfully treated with intravenous immunoglobulin. Scand J Rheumatol. 2018;47(2):168–169. doi:10.1080/03009742.2017.1393559
   PubMed Web of Science ®Google Scholar
• Kono Y, Omoto S, Sengoku R, et al. Multifocal conduction block in a patient with sarcoid neuropathy: successful treatment with intravenous immunoglobulin. Intern Med. 2013;52(9):999–1002. doi:10.2169/internalmedicine.52.7788
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6(5):389–402. doi:10.1016/S2213-2600(18)30064-X
   PubMed Web of Science ®Google Scholar
• Nunes H, Soler P, Valeyre D. Pulmonary sarcoidosis. Allergy. 2005;60(5):565–582. doi:10.1111/j.1398-9995.2005.00778.x
   PubMed Web of Science ®Google Scholar
• Sweiss N, Patterson K, Sawaqed R, et al. Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med. 2010;31(04):463–473. doi:10.1055/s-0030-1262214
   PubMed Web of Science ®Google Scholar
• Cohen Aubart F, Nunes H, Mathian A, et al. Sarcoïdose cardiaque: avancées diagnostiques et thérapeutiques. La Revue de Médecine Interne. 2017;38(1):28–35. doi:10.1016/j.revmed.2016.03.003
   PubMed Web of Science ®Google Scholar
• Birnie D, Beanlands RSB, Nery P, et al. Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). Am Heart J. 2020;220:246–252. doi:10.1016/j.ahj.2019.10.003
   PubMed Web of Science ®Google Scholar
• Groen F, Rothova A. Ocular involvement in sarcoidosis. Semin Respir Crit Care Med. 2017;38(04):514–522. doi:10.1055/s-0037-1602382
   PubMed Web of Science ®Google Scholar
• Sève P, Jamilloux Y, Tilikete C, Gerfaud-Valentin M, Kodjikian L, El Jammal T. Ocular sarcoidosis. Semin Respir Crit Care Med. 2020.
   PubMed Web of Science ®Google Scholar
• Dai C, Shih S, Ansari A, Kwak Y, Sami N. Biologic therapy in the treatment of cutaneous sarcoidosis: a literature review. Am J Clin Dermatol. 2019;20(3):409–422. doi:10.1007/s40257-019-00428-8
   PubMed Web of Science ®Google Scholar
• Wanat KA, Rosenbach M. Cutaneous sarcoidosis. Clin Chest Med. 2015;36(4):685–702. doi:10.1016/j.ccm.2015.08.010
   PubMed Web of Science ®Google Scholar
• Edriss H, Kelley JS, Demke J, Nugent K. Sinonasal and laryngeal sarcoidosis—an uncommon presentation and management challenge. Am J Med Sci. 2019;357(2):93–102. doi:10.1016/j.amjms.2018.11.007
   PubMed Web of Science ®Google Scholar
• Voortman M, Drent M, Baughman RP. Management of neurosarcoidosis: a clinical challenge. Curr Opin Neurol. 2019;32(3):475–483. doi:10.1097/WCO.0000000000000684
   PubMed Web of Science ®Google Scholar
• Mahevas M, Simon T, Audard V, et al. Résultats de l’étude Corticoïdose. Étude prospective multicentrique randomisée comparant l’efficacité et la tolérance des bolus de méthylprednisolone dans la sarcoïdose rénale. La Revue de Médecine Interne. 2017;38:A43. doi:10.1016/j.revmed.2017.10.308
   Google Scholar